Launxp Biomedical Co Ltd
TPEX:6876
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for Launxp Biomedical Co Ltd.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Launxp Biomedical Does
LAUNXP Biomedical Co. Ltd. is engaged in the development of medicines for tumor therapies. The company is headquartered in Taichung, Taichung. The company went IPO on 2024-01-18. The firm mainly develops cancer drugs. The main products include LXPA1788, LXPA1988, LXPA5948, LXPB5268, LXPB5101, LXPB8101, LXPB9568, LXPB977 and others. LXPA1788 is a new ingredient and new drug, a multi-target kinase inhibitor.
- Headquarters
- Taiwan TW
- Employees
- 35
- IPO date
- Jan 18, 2024
Balance Sheet
Continue Research
Decided on Launxp Biomedical? Get an email when Launxp Biomedical Co Ltd reaches the price you’d buy at. Free with an account.